Comprehensive Document about the Handling of OOE and OOT Results
Recommendation
Thursday, 29 October 2026 9 .00 - 14.00 h
Practical Approaches for Assessing the Risks of Impurities
On the Road to 30,000 Members
Let us become the World's Leading GMP/GDP Compliance Community in 2026
How are OOE and OOT results in the pharmaceutical industry to be recorded and assessed nowadays? To answer this question, the ECA Quality Control Working Group and representatives from authorities and industry compiled a guidance document about the handling of Out-of-Expectation (OOE) and Out-of-Trend (OOT) results.
This 70 page document covers the following issues:
- Regulatory references
- Overview of data management in the laboratory and the analytical process
- Responsibilities for QC and QA
- Purpose of trend analysis
- The concept of control charts
- Detection and handling of OOE results
- Statistical process control (SPC) of continuous and discrete data
- Techniques for the retrospective review of historical data
- Trend analysis in stability testing
This document also includes seven Annexes; a technical glossary and worked examples to visualize the most important statistical tools and regression methods for a proper setting of stability trend limits.
Related GMP News
21.10.2026EMA Updates Information Page on Bioequivalence Guidelines
21.10.2026BP Publishes new Draft Texts
21.10.2026FDA Identifies Critical Deficiencies in Analytical Testing and CGMP Oversight
07.10.2026Analytical Quality Group Developments May through August 2026
07.10.2026Two New FDA Warning Letters Put OOS Investigations in Focus
07.10.2026Pharmeuropa: Revision Proposed for Chapter 2.5.32 on Coulometric Karl Fischer Water Determination